Wanbury Limited has reached a significant commercial milestone with the completion of its first sales invoicing and commercial shipment of newly launched anaesthetic Active Pharmaceutical Ingredients (APIs) on January 30, 2026. The company successfully shipped products to a European customer from its Tanuku facility, demonstrating rapid market adoption and operational excellence following the recent product launch.

Commercial Milestone and Market Validation

The company has achieved a game-changing milestone with official confirmation of first sales, customer invoicing, and commercial shipment to a European customer for its newly commercialized anaesthetic API from the Tanuku facility. This achievement validates global demand and positions Wanbury for high-growth acceleration in the specialized pharmaceutical ingredients market.

Leadership Perspective and Growth Outlook

Mr. Mohan Rayana, Whole-time Director of Wanbury Limited, declared that "First sales confirmed, invoicing and product shipment completed, production scaling fast. Our expansion momentum positions us for exponential growth and market leadership." The rapid transition from product launch to commercial shipment reflects the company's effective market penetration strategy and operational capabilities.

Revenue Projections and Strategic Impact

The successful commercial shipment supports Wanbury's ambitious revenue target of ₹100.00 crore from these anaesthetic APIs by FY 2026-27. Just months after launching commercial production, the company has secured orders and completed invoicing, demonstrating strong market demand for these specialized pharmaceutical ingredients.

Manufacturing Excellence and Market Position

The successful completion of first commercial shipment from the Tanuku facility demonstrates Wanbury's operational excellence and market-leading product quality. The facility's USFDA and EUGMP approvals enable the company to serve global markets, with this European shipment marking the beginning of international market penetration for the new anaesthetic API portfolio. This success story is set to multiply as the company ramps up production capacity at Tanuku, strengthening Wanbury's position in the specialized pharmaceutical ingredients market.

Wanbury Limited has announced key board decisions regarding the re-appointment of its Independent Director and scheduling of an Extraordinary General Meeting. The pharmaceutical company's board meeting held on December 10, 2025, addressed important governance matters requiring shareholder approval.

Board Approves Director Re-appointment

The Board of Directors approved the re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director. His current tenure is set to end on January 7, 2026, and the proposed re-appointment will be effective from January 8, 2026, to January 7, 2027.

Mr. Gursahani has confirmed that he continues to meet the criteria of independence under the provisions of the Companies Act, 2013, and the SEBI Listing Regulations.

Extraordinary General Meeting Scheduled

The board has approved the issuance of notice for convening an Extraordinary General Meeting (EGM) of shareholders. The meeting is scheduled for Monday, January 5, 2026, to seek necessary approval from shareholders for the re-appointment through a special resolution.

Director Profile and Experience

Mr. Manojkumar Khubchand Gursahani brings over 30 years of professional experience to the board. He is a distinguished thought leader holding a graduate degree from Mumbai University and serves as a TED speaker, global strategist, and author of "The Human Connect."

His professional accomplishments include:

• Co-founder of Vera Healthcare Technologies, an AI-driven platform for early detection of ocular diseases
• Executive Director at the Global Chamber
• Mumbai Chair for the Las Vegas Chamber of Commerce
• Managing Trustee of the Indian Relief Foundation
• Advisor to Lion Tarachand Bapa Hospital
• Immediate Past President of the Rotary Club of Queens Necklace, Mumbai

Compliance and Independence

The company has confirmed that Mr. Gursahani is not related to any of the directors of the company and is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. This ensures compliance with regulatory requirements for independent directors.

Meeting Details

The board meeting commenced at 4:30 PM and concluded at 5:15 PM on December 10, 2025. The company has informed both BSE Limited and National Stock Exchange of India about these decisions in accordance with Regulation 30 of the SEBI Listing Regulations.